vs
ARDELYX, INC.（ARDX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是ARDELYX, INC.的1.5倍（$188.3M vs $125.2M），BRC Group Holdings, Inc.净利率更高（47.9% vs -0.3%，领先48.3%），ARDELYX, INC.同比增速更快（7.8% vs -21.9%），过去两年ARDELYX, INC.的营收复合增速更高（64.9% vs -15.4%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
ARDX vs RILY — 直观对比
营收规模更大
RILY
是对方的1.5倍
$125.2M
营收增速更快
ARDX
高出29.7%
-21.9%
净利率更高
RILY
高出48.3%
-0.3%
两年增速更快
ARDX
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $188.3M |
| 净利润 | $-407.0K | $90.3M |
| 毛利率 | 91.3% | 79.5% |
| 营业利润率 | 4.1% | 32.3% |
| 净利率 | -0.3% | 47.9% |
| 营收同比 | 7.8% | -21.9% |
| 净利润同比 | -108.8% | 1710.8% |
| 每股收益（稀释后） | $-0.01 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXRILY
| Q4 25 | $125.2M | $188.3M | ||
| Q3 25 | $110.3M | $215.3M | ||
| Q2 25 | $97.7M | $188.2M | ||
| Q1 25 | $74.1M | $197.2M | ||
| Q4 24 | $116.1M | $241.0M | ||
| Q3 24 | $98.2M | $225.5M | ||
| Q2 24 | $73.2M | $256.0M | ||
| Q1 24 | $46.0M | $263.4M |
净利润ARDXRILY
| Q4 25 | $-407.0K | $90.3M | ||
| Q3 25 | $-969.0K | $91.1M | ||
| Q2 25 | $-19.1M | $139.5M | ||
| Q1 25 | $-41.1M | $-10.0M | ||
| Q4 24 | $4.6M | $-5.6M | ||
| Q3 24 | $-809.0K | $-284.4M | ||
| Q2 24 | $-16.5M | $-433.6M | ||
| Q1 24 | $-26.5M | $-49.2M |
毛利率ARDXRILY
| Q4 25 | 91.3% | 79.5% | ||
| Q3 25 | 96.4% | 83.7% | ||
| Q2 25 | 87.3% | 81.3% | ||
| Q1 25 | 83.4% | 81.4% | ||
| Q4 24 | 84.3% | 79.8% | ||
| Q3 24 | 84.0% | 82.1% | ||
| Q2 24 | 87.1% | 84.5% | ||
| Q1 24 | 84.5% | 85.3% |
营业利润率ARDXRILY
| Q4 25 | 4.1% | 32.3% | ||
| Q3 25 | 4.2% | 30.4% | ||
| Q2 25 | -14.7% | 5.7% | ||
| Q1 25 | -49.0% | -31.2% | ||
| Q4 24 | 7.0% | -69.2% | ||
| Q3 24 | 2.3% | -36.4% | ||
| Q2 24 | -18.6% | -90.8% | ||
| Q1 24 | -53.6% | -6.1% |
净利率ARDXRILY
| Q4 25 | -0.3% | 47.9% | ||
| Q3 25 | -0.9% | 42.3% | ||
| Q2 25 | -19.5% | 74.1% | ||
| Q1 25 | -55.5% | -5.1% | ||
| Q4 24 | 4.0% | -2.3% | ||
| Q3 24 | -0.8% | -126.1% | ||
| Q2 24 | -22.5% | -169.4% | ||
| Q1 24 | -57.6% | -18.7% |
每股收益（稀释后）ARDXRILY
| Q4 25 | $-0.01 | $2.78 | ||
| Q3 25 | $0.00 | $2.91 | ||
| Q2 25 | $-0.08 | $4.50 | ||
| Q1 25 | $-0.17 | $-0.39 | ||
| Q4 24 | $0.01 | $-0.01 | ||
| Q3 24 | $0.00 | $-9.39 | ||
| Q2 24 | $-0.07 | $-14.35 | ||
| Q1 24 | $-0.11 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $226.6M |
| 总债务越低越好 | $202.8M | $1.4B |
| 股东权益账面价值 | $166.9M | $-171.5M |
| 总资产 | $501.6M | $1.7B |
| 负债/权益比越低杠杆越低 | 1.21× | — |
8季度趋势，按日历期对齐
现金及短期投资ARDXRILY
| Q4 25 | $68.0M | $226.6M | ||
| Q3 25 | $42.7M | $184.2M | ||
| Q2 25 | $90.0M | $267.4M | ||
| Q1 25 | $30.8M | $138.3M | ||
| Q4 24 | $64.9M | $146.9M | ||
| Q3 24 | $47.4M | $159.2M | ||
| Q2 24 | $41.9M | $236.9M | ||
| Q1 24 | $36.1M | $190.7M |
总债务ARDXRILY
| Q4 25 | $202.8M | $1.4B | ||
| Q3 25 | $202.1M | $1.3B | ||
| Q2 25 | $201.4M | $1.3B | ||
| Q1 25 | $151.3M | $1.4B | ||
| Q4 24 | $150.9M | $1.5B | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — | ||
| Q1 24 | $99.8M | — |
股东权益ARDXRILY
| Q4 25 | $166.9M | $-171.5M | ||
| Q3 25 | $154.3M | $-260.5M | ||
| Q2 25 | $139.5M | $-351.7M | ||
| Q1 25 | $145.7M | $-496.8M | ||
| Q4 24 | $173.3M | $-488.2M | ||
| Q3 24 | $158.3M | $-497.6M | ||
| Q2 24 | $147.0M | $-218.3M | ||
| Q1 24 | $150.9M | $228.4M |
总资产ARDXRILY
| Q4 25 | $501.6M | $1.7B | ||
| Q3 25 | $486.2M | $1.7B | ||
| Q2 25 | $466.8M | $1.5B | ||
| Q1 25 | $410.2M | $1.5B | ||
| Q4 24 | $435.8M | $1.8B | ||
| Q3 24 | $367.9M | $2.2B | ||
| Q2 24 | $343.5M | $3.2B | ||
| Q1 24 | $342.4M | $5.0B |
负债/权益比ARDXRILY
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.0M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $20.6M | — |
| 自由现金流率自由现金流/营收 | 16.4% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-44.0M | — |
8季度趋势，按日历期对齐
经营现金流ARDXRILY
| Q4 25 | $21.0M | $26.2M | ||
| Q3 25 | $365.0K | $-60.6M | ||
| Q2 25 | $-25.3M | $-25.6M | ||
| Q1 25 | $-38.5M | $184.0K | ||
| Q4 24 | $9.8M | $-2.7M | ||
| Q3 24 | $501.0K | $19.5M | ||
| Q2 24 | $-19.4M | $111.5M | ||
| Q1 24 | $-35.7M | $135.4M |
自由现金流ARDXRILY
| Q4 25 | $20.6M | — | ||
| Q3 25 | $209.0K | — | ||
| Q2 25 | $-26.0M | — | ||
| Q1 25 | $-38.8M | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $364.0K | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-35.9M | — |
自由现金流率ARDXRILY
| Q4 25 | 16.4% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | -26.6% | — | ||
| Q1 25 | -52.3% | — | ||
| Q4 24 | 7.9% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | -26.7% | — | ||
| Q1 24 | -77.9% | — |
资本支出强度ARDXRILY
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.3% | — |
现金转化率ARDXRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| Product IBSRELA | $86.6M | 69% |
| Product XPHOZAH | $27.8M | 22% |
| Other | $10.8M | 9% |
| Non Cash Royalty Related To Sale Of Future Royalties | $1.4M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
